What are the side effects of Rozelixizumab?

Rozanolixizumab (Rozanolixizumab) is a monoclonal antibody targeting the FcRn receptor. It is mainly used to treat autoimmune diseases such as myasthenia gravis (gMG; rare disease ) driven by autoantibodies. By reducing circulating immunoglobulin G (IgG) levels in the body, roselixizumab can effectively reduce the concentration of pathogenic autoantibodies, thereby alleviating symptoms. Although the drug has shown good efficacy and tolerability globally, as a new type of targeted immunomodulatory drug, there are still some side effects that require patients and clinicians to pay close attention to.

Among the most common adverse reactions, injection site reactions are one of the most frequent problems with roselixizumab. These reactions usually manifest as redness, pain, itching or local induration, usually occur within 24 hours after injection, are mostly mild to moderate, and can resolve on their own. To reduce the risk of local irritation, patients are advised to alternate injection sites and clean and protect the skin before and after infusion.

In addition to local reactions, systemic adverse reactions are also worth noting. The most common systemic symptoms include headache, nausea, diarrhea and fatigue, which are often related to a sharp drop in IgG levels in the body, especially after the first few doses. Although most symptoms are mild, patients with poor immune function or multiple comorbidities should be monitored more closely to prevent minor symptoms from turning into more serious complications.

The increased risk of infection is one of the important precautions when using anti-FcRn drugs. Because the drug can significantly reduce IgG concentrations, thereby affecting antibody-mediated immune defense, some patients may be more susceptible to upper respiratory tract infections, pneumonia, or urinary tract infections. Clinically, it is recommended that patients complete basic vaccinations before use, especially vaccines that do not contain live virus components, such as pneumococcal and herpes zoster vaccines, to enhance their defense capabilities.

Reference materials:https://www.drugs.com/rystiggo.html